PTC Therapeutics
PTCT
$28.57
Share price
12.08%
Change (1 day)
-45.73%
Change (1 year)
Categories
P/S ratio for PTC Therapeutics (PTCT)
P/S ratio as of April 2024 (TTM): 2.34
According to PTC Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.34034. At the end of 2023 the company had a P/S ratio of 2.22.
P/S ratio history for PTC Therapeutics from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.22 | -44.37% |
| 2022 | 3.99 | -23.76% |
| 2021 | 5.23 | -52.2% |
| 2020 | 10.9 | 12.86% |
| 2019 | 9.69 | 47.71% |
| 2018 | 6.56 | 84.28% |
| 2017 | 3.56 | -21.36% |
| 2016 | 4.53 | -83.83% |
| 2015 | 28.0 | -62.25% |
| 2014 | 74.2 | 475.16% |
| 2013 | 12.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.90 | 66.53% | 🇨🇭 Switzerland |
 Vertex Pharmaceuticals VRTX | 10.4 | 345.04% | 🇺🇸 USA |
 Xencor XNCR | 7.33 | 213.11% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | 9.81 | 318.97% | 🇺🇸 USA |
 Fate Therapeutics
FATE | 6.81 | 191.17% | 🇺🇸 USA |
 Avidity Biosciences RNA | 203 | 8,593.95% | 🇺🇸 USA |